AI-generated summary
The authors report a case of one woman in her early 30s with recalcitrant melasma treated with a picosecond 755 nm laser, topical tofacitinib 2% cream and visible light-blocking photoprotection over 11 months. Her Melasma Severity Index fell from 7.9 to 0.10, with no adverse events or relapse reported, including 3 months after stopping treatment. The authors describe this as a single case that supports further investigation of the combined approach.
- Who or what was studied
- One woman in her early 30s with Fitzpatrick phototype IV and recalcitrant centrofacial melasma
- Wavelengths
- 755 nm
- Limits stated in the abstract
- The report describes a single patient without a control group, so the findings cannot be generalized.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Melasma is a chronic hyperpigmentation disorder with high relapse rates, particularly in Fitzpatrick skin types III-V. Increasing evidence implicates cytokine-driven inflammation and visible light-induced melanogenesis as key contributors to disease persistence. These mechanisms support the rationale for exploring a multimodal therapeutic approach. CASE PRESENTATION: A woman in her early 30s with phototype IV presented with a 5-year history of recalcitrant centrofacial melasma. Previous treatments-including hydroquinone, oral tranexamic acid, and superficial chemical peels-produced only transient and incomplete improvement. Baseline Melasma Severity Index (MSI) score was 7.9, consistent with moderate-to-severe disease.
Intervention
Treatment consisted of low-fluence picosecond 755 nm alexandrite laser, short-term topical corticosteroid post-procedure, initiation of topical tofacitinib 2% cream twice daily for 11 months, and continuous iron oxide-based visible light-blocking photoprotection. Laboratory monitoring during therapy remained normal. OUTCOME: At 11 months, the patient achieved near-total clearance with an MSI reduction from 7.9 to 0.10 (98.7% improvement). No adverse events, post-inflammatory hyperpigmentation, or relapse were observed, including 3 months after treatment cessation.
Conclusion
This case illustrates the potential clinical value of combining pigment-targeted picosecond laser therapy with topical JAK inhibition and visible light-specific photoprotection for recalcitrant melasma. The durable remission achieved supports further investigation into anti-inflammatory and photoreactive pathway modulation as adjunctive strategies in melasma management.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 755 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Case report, Inflammation, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.